Welcome!

News Feed Item

US Excipients Market



 

 

 

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:



US Excipients Market

http://www.reportbuyer.com/pharma_healthcare/general_industry/us_excipients_market.html


US demand to grow 4.3% annually through 2018

Demand for pharmaceutical excipients in the US is projected to rise 4.3 percent per year to $2.0 billion in 2018. In volume terms, demand is expected to grow 1.9 percent annually to 900 million pounds over the same period. While continued growth in pharmaceutical output will be the primary driver of increases in excipient demand, gains will accelerate as excipients play a larger role in bringing additional value to pharmaceutical products by improving properties such as the controlled release or improved
absorption of active ingredients.


Preservatives, suspension agents to see strong gains

Trends in pharmaceutical output by dosage formulation will have a strong influence on excipient demand by application. Output of parenteral preparations is expected to rise at an especially strong pace through 2018, supporting demand for suspension agents and preservatives. Solvents are also projected to benefit from increased shipments of parenteral drugs, although gains in dollar terms will be limited by the continued decline in glycerin prices due to oversupply.
Oral preparations are the largest category of pharmaceutical dosage formulations; thus, oral pharmaceuticals tend to require more excipients than other types of drugs and have a significant impact on excipient demand. Shipments of oral pharmaceuticals are forecast to rise at a faster pace than seen in the 2008-2013 period, supporting accelerated gains in demand for fillers, binders, coatings, flavoring agents, capsules, and disintegrants. In addition, oral formulations such as delayed- and extended-release tablets and capsules and dissolving tablets are expected to boost their market share, further raising demand for excipients such as binders and disintegrants.


Specialty excipient blends to add value to product mix

A major development in the excipient and pharmaceutical industries is the increased dependence on specialty excipient blends. Specialty excipient blends can add value to pharmaceutical products by differentiating them from competitive products, and by optimizing the production process. These value-added excipient blends are often formulated for usage in specific manufacturing processes such as direct compression or wet granulation, and are optimized for certain performance characteristics such as delayed- or extended-release oral tablets. Product differentiation will play an increasingly important role going forward as generic pharmaceutical products increase their market share and as consumers take a more active role in choosing their drugs from among a wide range of products with the same active pharmaceutical ingredients.


Polymers to benefit from specialty blend advances

Product versatility will be a key factor impacting product mix in excipient demand going forward, especially as specialty excipient blends play an increasingly important role in pharmaceutical formulation. Polymers -- including cellulose derivatives, povidone, starch, polyethylene glycol, acrylic polymers, and natural gums -- are expected to benefit from this trend as many of these products can function in multiple applications and are easily formulated with other excipients. These favorable characteristics will serve to offset the higher prices associated with some polymers.


Study coverage

Excipients, an upcoming industry study presents historical demand data (2003, 2008, 013) plus forecasts for 2018 and 2023 by product type and application. This study also analyzes market environment factors, evaluates company market share and profiles 47 US industry competitors.
INTRODUCTION x
I. EXECUTIVE SUMMARY 1
II. MARKET ENVIRONMENT 4
General 4
Economic Factors 5
Demographic Patterns 9
Health Care Trends 13
National Health Expenditures 14
Medical Conditions 17
Chronic Conditions 18
Acute Conditions 20
Pharmaceuticals 22
Therapeutic Class 23
Dosage Formulations 24
Distribution Classifications 26
Commercial Status 28
Regulatory Overview 29
Historical Market Trends 31
Pricing Trends 32
Foreign Trade 34
International Markets 35
III. PRODUCTS 37
General 37
Polymers 43
Cellulose Derivatives 46
Microcrystalline Cellulose (MCC) 47
Hydroxypropyl Methylcellulose (HPMC) 50
Ethyl Cellulose 54
Methyl Cellulose 55
Carboxymethylcellulose (CMC) 57
Croscarmellose Sodium 59
Other Cellulose Excipients 61
Povidone 64
Starch Compounds 67
Pregelatinized Starch 69
Sodium Starch Glycolate 71
Other Starch Excipients 73
Polyethylene Glycol 77
Acrylic Polymers 80
Other Polymers 84
Natural Gums from Seaweeds 85
Other Natural Gums 88
All Other Polymers 90
Alcohols 91
Propylene Glycol 93
Glycerin 94
Sorbitol 96
Other Alcohols 98
Mannitol 99
Other Polyol Excipients 100
All Other Alcohols 104
Minerals 104
Calcium Phosphate 107
Calcium Carbonate 109
Clay 110
Mineral Hydrocarbons 112
Silicon Dioxide 115
Titanium Dioxide 117
Other Minerals 118
Gelatin 121
Sugars 125
Lactose 127
Sucrose 129
Other Sugar Excipients 131
Other Pharmaceutical Excipients 134
Dyes & Pigments 137
Flavors 138
Surfactants 139
Acidulants 142
Antioxidants & Antimicrobials 143
All Other Compounds 145
Stearate Compounds 145
Electrolytes & Related Compounds 146
Chemical Plasticizers 146
High Intensity Sweeteners 147
Natural Fats & Oils 149
Natural Waxes 150
IV. APPLICATIONS 152
General 152
Fillers & Diluents 155
Binders 157
Suspension & Viscosity Agents 160
Coatings 162
Solvents 164
Flavoring Agents 166
Capsules 168
Disintegrants 171
Colorants 173
Lubricants & Glidants 174
Preservatives 176
Other Applications 177
V. INDUSTRY STRUCTURE 179
General 179
Market Share 181
Competitive Strategies 184
Industry Restructuring 185
Cooperative Agreements 187
Marketing & Distribution 191
Research & Development 192
Manufacturing 193
Company Profiles 194
ABITEC, see Associated British Foods
Akzo Nobel NV 195
ANGUS Chemical, see Dow Chemical
Archer-Daniels-Midland Company 196
Ashland Incorporated 198
Associated British Foods plc 201
Avantor Performance Materials Incorporated 204
BASF SE 206
Berkshire Hathaway Incorporated 209
Berwind Corporation 211
Cabot Corporation 213
Cargill Incorporated 215
Celanese Corporation 218
Colorcon, see Berwind
Corn Products International, see Ingredion
CP Kelco US, see Huber (JM)
Croda International plc 220
CyDex Pharmaceuticals, see Ligand Pharmaceuticals
Dow Chemical Company 222
DuPont (EI) de Nemours 227
Eastman Chemical Company 229
EMD Millipore, see Merck
Evonik Industries AG 231
Ferro Corporation 234
FibroGen Incorporated 235
FLAVORx Incorporated 236
FMC Corporation 237
GELITA AG 239
Generichem Corporation 240
Huber (JM) Corporation 241
Huntsman Corporation 244
Ingredion Incorporated 245
Innophos Holdings Incorporated 247
JRS Pharma, see Rettenmaier (J.) & Söhne
Kraft Foods Group Incorporated 248
Kuraray Company Limited 249
Ligand Pharmaceuticals Incorporated 250
Lubrizol, see Berkshire Hathaway
LyondellBasell Industries NV 252
Merck KGaA 253
Mutchler Incorporated 255
Nitta Gelatin Incorporated 256
NutraSweet Company 257
Nutrinova, see Celanese
P&G Chemicals, see Procter & Gamble
PB Gelatins, see Tessenderlo Group
Pfanstiehl Incorporated 258
Procter & Gamble Company 259
Rettenmaier (J.) & Söhne GmbH & Company KG 260
Roquette Frères SA 262
Royal Dutch Shell plc 265
Sasol Limited 266
Shin-Etsu Chemical Company Limited 268
Solvay SA 270
SPI Pharma, see Associated British Foods
Stepan Company 271
Tate & Lyle plc 273
Tessenderlo Group NV 275
USG Corporation 276
Wacker Chemie AG 277
Other Companies Mentioned in Study 280


LIST OF TABLES

SECTION I -- EXECUTIVE SUMMARY
Summary Table 3
SECTION II -- MARKET ENVIRONMENT
1 Macroeconomic Indicators 9
2 Population & Households 13
3 National Health Expenditures 17
4 Chronic Conditions by Type 20
5 Acute Conditions by Type 21
6 Pharmaceutical Supply & Demand 22
7 Pharmaceutical Shipments by Therapeutic Class 24
8 Pharmaceutical Shipments by Dosage Formulation 26
9 Pharmaceutical Shipments by Distribution Classification 28
10 Pharmaceutical Shipments by Commercial Status 29
11 Excipient Market, 2003-2013 32
12 Pharmaceutical Excipient Pricing 34
SECTION III -- PRODUCTS
1 Pharmaceutical Excipient Demand by Product Group 41
2 Polymer Excipient Demand by Type & Application 44
3 Cellulose Excipient Demand by Type & Application 47
4 Microcrystalline Cellulose Excipient Demand by Application 50
5 Hydroxypropyl Methylcellulose Excipient Demand
by Application 53
6 Ethyl Cellulose Excipient Demand by Application 55
7 Methyl Cellulose Excipient Demand by Application 57
8 Carboxymethylcellulose Excipient Demand by Application 59
9 Croscarmellose Sodium Excipient Demand 61
10 Other Cellulose Excipient Demand by Application 64
11 Povidone Excipient Demand by Application 67
12 Starch Excipient Demand by Type & Application 69
13 Pregelatinized Starch Excipient Demand by Application 71
14 Sodium Starch Glycolate Excipient Demand 73
15 Other Starch Excipient Demand by Application 74
16 Polyethylene Glycol Excipient Demand by Application 80
17 Acrylic Polymer Excipient Demand by Application 84
18 Other Polymer Excipient Demand by Type & Application 85
19 Alcohol Excipient Demand by Type & Application 92
20 Propylene Glycol Excipient Demand by Application 94
21 Glycerin Excipient Demand by Application 96
22 Sorbitol Excipient Demand by Application 98
23 Other Alcohol Excipient Demand by Type & Application 99
24 Mineral Excipient Demand by Type & Application 106
25 Calcium Phosphate Excipient Demand 108
26 Calcium Carbonate Excipient Demand 110
27 Clay Excipient Demand by Application 112
28 Mineral Hydrocarbon Excipient Demand by Application 115
29 Silicon Dioxide Excipient Demand by Application 117
30 Titanium Dioxide Excipient Demand 118
31 Other Mineral Excipient Demand by Application 121
32 Gelatin Excipient Demand by Application 125
33 Sugar Excipient Demand by Type & Application 126
34 Lactose Excipient Demand by Application 129
35 Sucrose Excipient Demand by Application 131
36 Other Sugar Excipient Demand by Application 134
37 Other Pharmaceutical Excipient Demand by Type & Application 136
SECTION IV -- APPLICATIONS
1 Pharmaceutical Excipient Demand by Application 154
2 Filler & Diluent Excipient Demand by Type 157
3 Binder Excipient Demand by Type 160
4 Suspension & Viscosity Excipient Demand by Type 162
5 Coating Excipient Demand by Type 164
6 Solvent Excipient Demand by Type 166
7 Flavoring Agent Excipient Demand by Type 168
8 Capsule Excipient Demand by Type 171
9 Disintegrant Excipient Demand by Type 172
10 Colorant Excipient Demand by Type 174
11 Lubricant & Glidant Excipient Demand by Type 175
12 Preservative Excipient Demand by Type 177
13 Other Applications for Excipients by Type 178
1 US Excipient Sales by Company, 2013 180
2 Selected Acquisitions & Divestitures 187
3 Selected Cooperative Agreements 189


LIST OF CHARTS

SECTION III -- PRODUCTS
1 Excipient Demand by Product: Value & Volume, 2013 42
2 Polymer Excipient Demand: Value & Volume, 2013 45
SECTION IV -- APPLICATIONS
1 Pharmaceutical Excipient Demand by Application, 2013 155
SECTION V -- INDUSTRY STRUCTURE
1 US Excipient Market Share, 2013 182


Read the full report:
US Excipients Market

http://www.reportbuyer.com/pharma_healthcare/general_industry/us_excipients_market.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
Akana has announced the availability of version 8 of its API Management solution. The Akana Platform provides an end-to-end API Management solution for designing, implementing, securing, managing, monitoring, and publishing APIs. It is available as a SaaS platform, on-premises, and as a hybrid deployment. Version 8 introduces a lot of new functionality, all aimed at offering customers the richest API Management capabilities in a way that is easier than ever for API and app developers to use.
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.